Welcome from the Conference Co-chairs
Sinata Koulla-Shiro (Cameroon)
Serge Eholié (Ivory Coast)
Elly Katabira (Uganda)
Catherine Hankins (Canada/The Netherlands)

9.10h Session: Antiretroviral Treatment Optimization
Chairs: Serge Eholié (Ivory Coast), Elly Katabira (Uganda)

09.10h Where Do We Stand in 2016
Andrew Hill, PhD, University of Liverpool (United Kingdom)

09.35h Q&A

09.40h Treatment Optimization: The Advocates’ Perspective
Speaker from the treatment advocacy pre-meeting

10.05h Q&A

10.10h Acquired Drug Resistance: Causes, Patterns, and Implications for SSA
Coumba Touré Kane, PharmD, PhD, Dakar University (Senegal)

10.35h Q&A

10.40h Round Table Discussion

11.00h Refreshment Break

11.30h Symposium: AbbVie - The Road to 2030
Chair: Sinata Koulla-Shiro (Cameroon)

11.30h Opening remarks by the chair

11.40h 90-90-90: Closing the Gaps
Sylvia Ojoo, MBChB, University of Maryland Kenya (Kenya)

12.05h Evolving Treatment Paradigms: Relevance in Resource-Limited Settings
Nicholas Paton, MD, FRCP, National University of Singapore (Singapore)

12.40h Q&A

12.55h Closing remarks

13.00h Lunch and Meet the Expert Opportunity for Early Career Investigators

14.00h Session: Advances in Laboratory Science and Implementation
Chair: Pierre-Marie Girard (France)

14.00h Progress on viral load monitoring, laboratory quality assurance, point of care
John Nkengasong, PhD, Centers for Disease Control and Preventio (Cameroon/USA)

14.25h Q&A

14.30h Session: Emerging Pathogens in West-Africa: Lessons From and For HIV
Chairs: Peter Kilmarx (USA), Catherine Hankins (Canada/The Netherlands)

14.30h Introductory Remarks by the chairs
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.35h</td>
<td>Lessons learnt from Ebola Vaccine Trials in Emergency Settings</td>
</tr>
<tr>
<td></td>
<td><strong>Godwin Enwere, MD, MSc</strong>, World Health Organisation (Switzerland/Nigeria)</td>
</tr>
<tr>
<td>14.55h</td>
<td>Lessons learnt from Ebola Therapeutic Trials and Survivor Cohort Studies</td>
</tr>
<tr>
<td></td>
<td><strong>Daouda Sissoko, MD</strong>, Bordeaux Hospital University Center (Guinea/France)</td>
</tr>
<tr>
<td>15.15h</td>
<td>Lessons learnt About Good Participatory Practices in Prevention and Treatment Trials for HIV and Emerging Pathogens</td>
</tr>
<tr>
<td></td>
<td><strong>Lillian Mutengu</strong>, International AIDS Vaccine Initiative (IAVI) (Kenya)</td>
</tr>
<tr>
<td>15.35h</td>
<td>Lessons learnt About the Ethics of Trial Conduct in Emergency Settings</td>
</tr>
<tr>
<td></td>
<td><strong>Morenike Ukpong Folayan</strong>, Obafemi Awolowo University (Nigeria)</td>
</tr>
<tr>
<td>15.55h</td>
<td>Ebola to Lassa Fever: Lessons learnt</td>
</tr>
<tr>
<td></td>
<td><strong>Ismail Abdus Salang</strong>, Lagos State Ministry of Health (Nigeria)</td>
</tr>
<tr>
<td>16.35h</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>16.50h</td>
<td>Refreshment Break</td>
</tr>
<tr>
<td>17.30h</td>
<td>Session: Official Opening Session</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> <strong>Sinata Koulla-Shiro</strong> (Cameroon), <strong>Serge Eholié</strong> (Ivory Coast)</td>
</tr>
<tr>
<td>17.30h</td>
<td>Introduction</td>
</tr>
<tr>
<td>17.40h</td>
<td>Welcome address</td>
</tr>
<tr>
<td></td>
<td><strong>by the Yaoundé City Council Government Delegate</strong></td>
</tr>
<tr>
<td>17.45h</td>
<td>Opening speech</td>
</tr>
<tr>
<td></td>
<td><strong>by the Minister of Health</strong> (Cameroon)</td>
</tr>
<tr>
<td>18.00h</td>
<td>HIV in Cameroon</td>
</tr>
<tr>
<td></td>
<td><strong>Elat Mfetam Jean Bosco</strong>, Permanent Secretary, NAC (Cameroon)</td>
</tr>
<tr>
<td>18.20h</td>
<td>Progress in HIV Prevention and Treatment Scale-Up in Sub-Saharan Africa</td>
</tr>
<tr>
<td></td>
<td><strong>Claire Mulanga</strong>, UNAIDS Cameroon Office (Democratic Republic of Congo/Cameroon)</td>
</tr>
<tr>
<td>18.40h</td>
<td>The Joep Lange Institute / Art and Science in the HIV response</td>
</tr>
<tr>
<td></td>
<td><strong>Brandon O’Dell</strong> (USA/the Netherlands) <strong>Alexender Kohnstamm</strong> (the Netherlands), The Joep Lange Institute, the Netherlands</td>
</tr>
<tr>
<td>19.00h</td>
<td>Opening Rooftop Reception</td>
</tr>
</tbody>
</table>

**WEDNESDAY 4 MAY 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.45h</td>
<td>Joep Lange Research Career Guidance Session and Grantspersonship Session (pre-registration required, space restricted).</td>
</tr>
<tr>
<td>09.00h</td>
<td>Session: Addressing 90-90-90 Implementation Challenges on the Road to 2020 and 2030</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> <strong>Debwerk Zewdie</strong> (Ethiopia/USA), <strong>François Venter</strong> (South Africa)</td>
</tr>
<tr>
<td>09.00h</td>
<td>HIV Testing Strategies: How to Reach 90% Knowledge of Serostatus (including the role of self-testing)</td>
</tr>
<tr>
<td></td>
<td><strong>Elizabeth Marum</strong>, Centers for Disease Control and Prevention (USA)</td>
</tr>
<tr>
<td>09.25h</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>09.30h</td>
<td>Immediate Offer of HIV Treatment: How To Deliver on the Second 90 (including Supply Chain Management and Drug Stockouts)</td>
</tr>
<tr>
<td></td>
<td><strong>Roselyn Toby</strong>, Yaoundé Central Hospital/Ministry of Health (Cameroon)</td>
</tr>
<tr>
<td>09.55h</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>
10.00h  **Insights and Lessons Learned on Retention, Adherence, and Achieving and Maintaining Viral Suppression: The Third 90**  
Tsitsi Apollo, Ministry of Health (Zimbabwe)

10.25h  Q&A

10.30h  **Refreshment Break and Poster Viewing**  
PP_09-PP_17 (poster discussion) P_27-P_35 (posters)

11.00h  **Symposium: Janssen Therapeutics - Continuum of Care for Children and Adolescents**

  **Chair:**  Alain Azondekon (Benin)

11.00h  Welcome: Objectives of the Satellite and Introduction of Faculty

11.05h  **Knowing Your Data - Update on the Epidemiology of HIV in Children and Adolescents**  
Landry Tsague, UNICEF Regional Office (Sénégal)

11.20h  Q&A

11.25h  **Being Proactive - HIV Prevention in Adolescents**  
Magdalene Mayer (Cameroon)

11.40h  Q&A

11.45h  **90-90-90 for all - Scale up of HIV Treatment for Adolescents**  
Victor Musiime, Joint Clinical Research Centre (Uganda)

12.05h  Q&A

12.10h  **Supporting Beyond Treatment - Care for HIV Positive Adolescents**  
Rama Diagne, (Sénégal)

12.25h  **Share Perspective of Young Person Living With HIV**  
Speaker to be confirmed

12.35h  **Staying on Track: Faculty Discussion and Q&A from the Audience**

12.55h  Closing Remarks by the Chair

13.00h  Lunch and Meet the Expert Opportunity for Early Career Investigators

14.00h  **Oral Abstracts (10 minute presentations, 5 minutes for Q&A)**

  **Chairs:**  Anna Laura Ross (France), Kenly Sikwese (Zambia)

14.00h  **Decline in positivity rates among HIV-exposed infants with changes in PMTCT ARV regimens in Nigeria: evidence from 7 years of field implementation**  
H. Khamofu (Nigeria)

14.15h  **Favourable outcomes of paediatric second-line protease inhibitor-based antiretroviral treatment in Uganda**  
R.S. Boerma (The Netherlands)

14.30h  **Transmitted Drug Resistance and First-line ART Treatment Outcomes in Ugandan Children**  
H. Mugerwa (Uganda)

14.45h  **Ultra-deep pyrosequencing of paediatric HIV-1 drug resistance and coreceptor suggests possible suitability of protease inhibitors and maraviroc at younger ages in Cameroon**  
J. Fokam (Italy)

15.00h  **Formal Debate: Resolved that 90-90-90 Cannot be Attained**

  **Chair:**  Peter Kilmarx (USA)

15.00h  Opening remarks and voting
15.05h  First speaker affirming the motion: Mauro Schechter (Brazil)
15.12h  First speaker opposing the motion: Badara Samb (Sénégal)
15.19h  Comments from the audience
15.45h  Second speaker affirming the motion: Isaac Tita (Cameroon)
15.49h  Second speaker opposing the motion: Kenly Sikwese (Zambia)
15.53h  Summation affirming the motion
15.55h  Summation opposing the motion
15.57h  Voting and Conclusion by the Chair

16.00h  Refreshment Break and Poster Viewing
       P_36-P_48

16.30h  Poster Discussions
       Chairs: Coumba Touré Kane (Sénégal), Guido Ferrari (USA)
       16.30h Prevalence of non-infectious co-morbidities among HIV-positive subjects stably treated with tenofovir, lamivudine and ritonavir-boosted lopinavir in Cameroon
       D. Fokom Victoire (Cameroon)
       16.35h Current profile of dermatological diseases and events during HIV in Dakar.
       N.M.Dia (Sénégal)
       16.40h Quality of life among HIV/AIDS patients on anti retro-viral therapy at Lethakane primary hospital (Botswana): a cross sectional study
       L. Kumboneki (Botswana)
       16.45h Maximizing EID opportunities using the DBS Mentor Approach in Rural HIV Clinics in South-Eastern Nigeria
       P. Anyanwu (Nigeria)
       16.50h Model-based pediatric dosing of ritonavir-boosted Darunavir: an alternative to WHO guidelines
       P. Mohammed (United Kingdom)
       16.55h Getting pregnant in antiretroviral clinical trials: women choice and safety needs. Experience from the ANRS12169-2LADY and ANRS12286-MOBIDIP trials
       A. Serris (France)
       17.00h Retention in care among HIV-infected pregnant mothers on lifelong antiretroviral therapy (art) in Uganda
       S. Muhumuza (Uganda)
       17.05h Immunologic Criteria are Poor Predictors of Virologic Outcomes: Implications for HIV Monitoring in a Large Treatment Program in Nigeria
       J. Okuma (Nigeria)
       17.10h Factors associated with virologic failure in HIV infected individuals in Mansa district, Zambia
       G. Mutaawe (Zambia)
       17.15h Discussion

       17.30h Introduction
       A.C. Bissek
       17.45h Dolutegravir in targeting the 90:90:90 ambition
       T. Lukiana
       18.20h Dolutegravir in the African Context: Real life, Real Patients – Case Study
       Panel Discussion
       A.C. Bissek, C. Kouanfack, T. Lukiana
       18.50h Q&A
THURSDAY 5 MAY 2016

07.45h  Joep Lange Research Career Guidance Session and Grantspersonship Session (pre-registration required, space restricted).

9.00h  Session: HIV prevention in 2016

Chairs:  Clint Trout (USA/Cameroon) Mauro Schechter (Brazil)

9.00h  Sustaining progress on scale-up of voluntary medical male circumcision (VMMC), including role of devices and early infant male circumcision
Zebedee Mwandi, MD, USAID (Malawi)

09.25h  Q & A

09.30h  Trial, post-trial, & demonstration project results for Pre-exposure Prophylaxis (PrEP)
Elizabeth Irungu, MBChB, MPH, Partners in Health Research and Development (Kenya)

09.55h  Q & A

10.00h  New evidence on oral and topical PrEP for women: rings, gels, injectables
Nyaradzo Mgodi, MBChB, MMed, University of Zimbabwe-UCSF (Zimbabwe)

10.25h  Q & A

10.30h  Refreshment break and poster viewing
PP_18-PP_26 (poster discussion) P_49-P_57

11.00h  Debate: Gilead: The Continent of Africa is Ready for HIV Pre-Exposure Prophylaxis (PreP) Implementation

Chair:  Catherine Hankins (The Netherlands/Canada)

11.00h  Opening Vote

11.05h  PreP
Catherine Hankins, MD, PhD, FRCP, CM, AIGHD (Canada/The Netherlands)

11.15h  Speaker for the Proposition
Elly Katabira, MD, FRCP, Makere University (Uganda)

11.35h  Speaker for the Opposition
François Venter, MD, University of Witwatersrand (South Africa)

11.55h  Rebuttal Speaker 1 Elly Katabira, (Uganda)

12.00h  Rebuttal Speaker 2 François Venter, (South Africa)

12.05h  Community Advocate
Stephen Watiti, Mildmay Hospital (Uganda)

12.15h  Debate from the floor

12.30h  Closing Vote

12.30h  Conference picture

13.00h  Lunch and early career investigator meet the expert

14.00h  Session: Oral abstracts (10 minute presentations, 5 minutes for Q&A)

Chairs:  Kenly Sikwese (Zambia), Peter Kilmarx (USA)
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00h</td>
<td>Predictors of HIV-testing in South African adolescents: schools-based testing, pregnancy and sexual experience</td>
<td>C. Carty (South Africa)</td>
</tr>
<tr>
<td>14.15h</td>
<td>EDCTP as a model for Europe-Africa partnership on HIV/AIDS research and capacity development: Examples from Cameroon</td>
<td>L.J. Pandya (The Netherlands)</td>
</tr>
<tr>
<td>14.30h</td>
<td>Accumulation of HIV-1 drug resistance after continued virological failure on first-line antiretroviral therapy in adults and children</td>
<td>T.S. Boender (The Netherlands)</td>
</tr>
<tr>
<td>14.45h</td>
<td>Tenofovir-containing first-line ART favourably reduce inflammation markers compared to thymidine analogue nucleoside reverse-transcriptase inhibitors</td>
<td>S. Kroeze (The Netherlands)</td>
</tr>
</tbody>
</table>

**15.00h Prevention Tools: Implementation and Discovery**

*Chairs: Guido Ferrari (USA), Coumba Touré Kane (Senegal)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.00h</td>
<td>Viral reservoirs and the promise of a cure</td>
<td>Cissy Kityo, MD, [Uganda]</td>
</tr>
<tr>
<td>15.25h</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>15.30h</td>
<td>Update on HIV vaccine strategies and trials: Active and passive immunization strategies</td>
<td>Hannah Kibuuka, MD, Makerere University [Uganda]</td>
</tr>
<tr>
<td>15.55h</td>
<td>Q &amp; A</td>
<td></td>
</tr>
</tbody>
</table>

**15.00h Refreshment break and poster viewing**

P_58-P_69

**16.00h Progress and challenges in reaching key populations**

*Chairs: François Venter (South Africa), Sinata Koulla-Shiro (Cameroon)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30h</td>
<td>Sex work in sub-Saharan Africa</td>
<td>Isidore Traoré, MD, PhD, [Burkina Faso]</td>
</tr>
<tr>
<td>16.55h</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>17.00h</td>
<td>Drug Use in sub-Saharan Africa: opportunities and challenges</td>
<td>Reyach Abdoool, MD, [Mauritius]</td>
</tr>
<tr>
<td>17.25h</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>17.30h</td>
<td>Men who have sex with men in sub-Saharan Africa</td>
<td>Iliassou Mfochive Njindam, MD, MPH, [Cameroon]</td>
</tr>
<tr>
<td>17.55h</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>18.00h</td>
<td>Panel discussion: Challenges in engaging key populations in HIV prevention in sub-Saharan Africa</td>
<td></td>
</tr>
</tbody>
</table>

**16.15h Poster discussions**

*Chairs: Anna Laura Ross, (France), Stefano Vella (Italy)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.15h</td>
<td>Finding the first 90% to achieve epidemic control</td>
<td>J. Masedza (Zambia)</td>
</tr>
<tr>
<td>18.20h</td>
<td>Operational research studies among MSM in Cameroon: Linkage to treatment challenges</td>
<td>U. Tamoufe (Cameroon)</td>
</tr>
<tr>
<td>18.25h</td>
<td>Pre-Clinical Evaluation of optimized Immunogens targeting the neutralizing epitopes in MPER of HIV envelope Glycoprotein</td>
<td>A.W. Bopda (USA)</td>
</tr>
<tr>
<td>18.30h</td>
<td>Identification of Rare HIV-1 Group N and HTLV-3 Strains in Rural South Cameroon</td>
<td>N. Ndemb (Nigeria)</td>
</tr>
</tbody>
</table>
18.35h  HIV-1 group O infection in Cameroon from 2006 to 2013: prevalence, genetic diversity, evolution and public health challenges
          A.F. Aghokeng  
          (Cameroon)

18.40h  The effect of antiretroviral naïve HIV-1 infection on the ability of autologous NK cells to produce IFNγ upon exposure to Plasmodium falciparum- infected Erythrocytes
          C. Sake Ngane  
          (Cameroon)

18.45h  Evaluating plasmatic biomarkers as disease signatures for the point of care monitoring of HIV-1 and comorbidities in resource limited regions.
          G. Nchinda  
          (Cameroon)

18.50h  Immune reconstitution and skewed responses after ART initiation in HIV I infected Ugandans
          K. Nganou Makamdop  
          (Uganda)

18.55h  Outcomes of second-line therapy in HIV positive adults attending for routine care at Yaoundé Central Hospital
          A.O. Mafotsing Fopoussi  
          (Cameroon)

19.15h  Final drinks and finger food on Conference Floor

FRIDAY 6 MAY 2015

07.45h  Joep Lange Research Career Guidance Session and Grantspersonship Session (pre-registration required, space restricted).

09.00h  Session: Hepatitis B and C, m-Health in HIV programmes

          Chairs: Pierre-Marie Girard  
          (France), Charles Boucher  
          (The Netherlands)

          09.00h  Progress in Hepatitis B and C in sub-Saharan Africa
          Magloire Biwole Sida, MD, University of Yaounde  
          (Cameroon)

          09.25h  Q & A

          09.30h  M-Health for HIV
          Cees Hesp, PharmAccess,  
          (The Netherlands)

          09.55h  Q & A

10.00h  Session: Global Health Strategies and Financing

          Chairs: Catherine Hankins  
          (Canada/The Netherlands)

          10.00h  Global Health in the Era of Ebola and Zika
          Kevin de Cock, Centers for Disease Control and Prevention  
          (Kenya/USA)

          10.25h  Q & A

          10.30h  HIV Leadership and Financing Strategies for Countries in sub-Saharan Africa
          Debrework Zewdie, PhD, Global HIV/AIDS Program of the World Bank,  
          (Ethiopia/USA)

          10.55h  Q & A

11.00h  Refreshment break and poster viewing

11.30h  Session: Sponsor symposium: Roche

          Chair  
          Knut Seifert

          Roche Global Access Program (GAP) in support of UNAIDS 90/90/90

          Speakers: Souleymane Soumare, TBS,  
          (Senegal)

          Souleymane Sawadogo, CDC Atlanta,  
          (USA)

12.30h  Reflections by the Conference Chairs of the 10th INTEREST Workshop

Closure of the Workshop